Skip to content

Public FDA record

Z-0843-2021: CareLink Personal Software Therapy Management Software Tool for Diabetes CareLink System Therapy Manageme

Recall record Z-0843-2021 for Medtronic Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0843-2021
Company in FDA record
Medtronic Inc.
FDA record creation date
Jan 11, 2021
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

Incomplete basal rate information may be transmitted leading to a potential for inappropriate change in therapy. During data upload, radio frequency (RF) interference can occur at any point from surrounding devices or equipment that may affect the data transfer between the insulin pump and the CareLink Personal or CareLink System Software.

Source facts

Action
On 11/19/2020, the firm sent an "URGENT FIELD SAFETY NOTIFICATION" Letter via email, fax, mail and/or phone to its U.S. Customer, and on 12/07/2020, the firm initiated O.U.S Notification using approved regional methods. The Notification Letter informs customers that after the release of an updated uploader software version the following issues/scenarios may result: 1. Some reports may be missing all programmed basal rates in the device. This may result in a blank value on the Device Settings report of the 24-hour basal total. 2. Some reports may only display certain programmed basal rates and some basal rates in the device may be missing from the reports. This may result in a miscalculation on the Device Settings report of the 24-hour basal total. The following reports may be affected by these issues include: Device Settings, Daily Review/Daily Details, Weekly Review, and Sensor & Meter Overview. These reports have been utilized to adjust therapy settings or to transfer settings from an old pump to a new pump. If all of the following are true, it could lead to either over- or under-delivery of insulin which may result in low blood glucose (hypoglycemia, loss of consciousness), and/or high blood glucose (hyperglycemia): a) adjustments were made to therapy settings or if therapy settings were transferred from one device to another, and b) these actions were taken based on a report generated using CareLink" uploader version 3.1.5.000 that has missing or incomplete basal rates, and c) you are using Manual Mode The Recalling Firm is instructing customers to: 1. Install the new CareLink" uploader version 3.1.6.000 available within the CareLink" software to each computer where you upload devices. To confirm your current uploader version or to learn how to install the latest uploader, see the FAQ section at the end of this letter. 2. If you have had insulin settings adjusted that may have been made based on an impacted CareLink" report, review your settings
Initiated
2020-11-12
Root cause
Device Design
Distribution
U.S. Nationwide O.U.S. Worldwide Refer to Associated Documents and uploaded Consignee Lists/Spreadsheets. -Australia New Zealand -Canada -EMEA -Greater China -India -Japan -Latin America -South Korea -Southeast Asia -US
Recall number
Z-0843-2021
Recall status
Open, Classified
CDRH record ID
184770
FDA record created
2021-01-11
Recall event number
86895

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗